ID   NCI-N87
AC   CVCL_1603
SY   NCI N87; N87; N-87; NCI-H87; H87; H-87; NCIN87
DR   BTO; BTO:0003053
DR   CLO; CLO_0008129
DR   EFO; EFO_0002841
DR   AddexBio; C0023002/4674
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5822
DR   BCRC; 60217
DR   BCRJ; 0350
DR   BioGRID_ORCS_Cell_line; 516
DR   BioSample; SAMN01120666
DR   BioSample; SAMN03473211
DR   BioSample; SAMN10987913
DR   cancercelllines; CVCL_1603
DR   CCRID; 1101HUM-PUMC000481
DR   CCRID; 3101HUMTCHu130
DR   CCRID; 4201HUM-CCTCC00256
DR   Cell_Model_Passport; SIDM01147
DR   ChEMBL-Cells; CHEMBL3307326
DR   ChEMBL-Targets; CHEMBL614197
DR   CLS; 305057
DR   Cosmic; 685598
DR   Cosmic; 687556
DR   Cosmic; 868236
DR   Cosmic; 887250
DR   Cosmic; 908461
DR   Cosmic; 1187286
DR   Cosmic; 1482074
DR   Cosmic; 1582431
DR   Cosmic; 1995594
DR   Cosmic; 2036661
DR   Cosmic; 2069775
DR   Cosmic; 2443800
DR   Cosmic; 2484955
DR   Cosmic; 2807636
DR   Cosmic; 2823228
DR   Cosmic-CLP; 908461
DR   DepMap; ACH-000427
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 908461
DR   GEO; GSM267420
DR   GEO; GSM267427
DR   GEO; GSM267434
DR   GEO; GSM267441
DR   GEO; GSM552366
DR   GEO; GSM562405
DR   GEO; GSM827404
DR   GEO; GSM828827
DR   GEO; GSM844665
DR   GEO; GSM887453
DR   GEO; GSM888533
DR   GEO; GSM1237678
DR   GEO; GSM1237703
DR   GEO; GSM1374768
DR   GEO; GSM1374769
DR   GEO; GSM1374770
DR   GEO; GSM1670272
DR   IARC_TP53; 305
DR   KCB; KCB 2010183YJ
DR   KCLB; 60113
DR   KCLB; 60187
DR   LiGeA; CCLE_561
DR   PharmacoDB; NCIN87_1151_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1603
DR   PubChem_Cell_line; CVCL_1603
DR   Ubigene; YC-C068
DR   Wikidata; Q54908217
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RX   PubMed=1676761;
RX   PubMed=2158397;
RX   PubMed=8806089;
RX   PubMed=8806092;
RX   PubMed=8806095;
RX   PubMed=18804159;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=26919099;
RX   PubMed=27102572;
RX   PubMed=27397505;
RX   PubMed=29435981;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MET genetic alteration cell panel (ATCC TCP-1036).
CC   Characteristics: Established from a nude mouse xenograft.
CC   Doubling time: 47 hours (PubMed=2158397); 86 hours (PubMed=25984343); 23 hours (PubMed=26919099); 47 hours (PubMed=29435981).
CC   HLA typing: A*01:01,23:01; B*07:02,37:01; C*02:02,07:02; DQB1*05:02,05:02; DRB1*15:01,15:01 (PubMed=25960936).
CC   HLA typing: A*23:01,23:01; B*07:02,37:01; C*02:02,02:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (ATCC=CRL-5822).
CC   Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (PubMed=26919099).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=1676761; ATCC=CRL-5822).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=61.23%; Native American=0%; East Asian, North=2.17%; East Asian, South=0%; South Asian=0%; European, North=20.57%; European, South=16.04% (PubMed=30894373).
CC   Caution: According to PubMed=1676761 the ethnicity of the donor is Caucasian, but exome analysis finds it to be mostly of African lineage.
CC   Misspelling: NU-N87; BioSample=SAMN01120666; PubMed=25960936; Note=Also in all the NCBI data records associated with the BioSample record.
CC   Discontinued: KCLB; 60187; probable.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): AddexBio=C0023002/4674; ATCC=CRL-5822; CCRID; Cosmic-CLP=908461; Technion Genomics Center BCF; PubMed=25877200; PubMed=27102572
ST   Amelogenin: X,Y
ST   CSF1PO: 8,12
ST   D10S1248: 13
ST   D12S391: 16,21
ST   D13S317: 8,11
ST   D16S539: 9,13
ST   D18S51: 17
ST   D19S433: 14,14.2
ST   D1S1656: 16
ST   D21S11: 30
ST   D22S1045: 14,15
ST   D2S1338: 23,24
ST   D2S441: 11,12
ST   D3S1358: 14
ST   D5S818: 12,13
ST   D6S1043: 12
ST   D7S820: 10,11
ST   D8S1179: 14,15
ST   DYS391: 10
ST   FGA: 20,21
ST   Penta D: 12
ST   Penta E: 5
ST   TH01: 7,9 (PubMed=27102572)
ST   TH01: 9 (AddexBio=C0023002/4674; ATCC=CRL-5822; CCRID; Cosmic-CLP=908461; Technion Genomics Center BCF; PubMed=25877200)
ST   TPOX: 9,11
ST   vWA: 15,16
DI   NCIt; C5473; Gastric tubular adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 48
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RA   Sekiguchi M., Suzuki T.;
RT   "Gastric tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994).
RX   PubMed=1676761; DOI=10.1093/jnci/83.13.938;
RA   Kim J.-H., Takahashi T., Chiba I., Park J.-G., Birrer M.J., Roh J.K.,
RA   De Lee H., Kim J.-P., Minna J.D., Gazdar A.F.;
RT   "Occurrence of p53 gene abnormalities in gastric carcinoma tumors and
RT   cell lines.";
RL   J. Natl. Cancer Inst. 83:938-943(1991).
RX   PubMed=2158397;
RA   Park J.-G., Frucht H., La Rocca R.V., Bliss D.P. Jr., Kurita Y.,
RA   Chen T.-R., Henslee J.G., Trepel J.B., Jensen R.T., Johnson B.E.,
RA   Bang Y.-J., Kim J.-P., Gazdar A.F.;
RT   "Characteristics of cell lines established from human gastric
RT   carcinoma.";
RL   Cancer Res. 50:2773-2780(1990).
RX   PubMed=8806089; DOI=10.1002/jcb.240630502;
RA   Gazdar A.F., Minna J.D.;
RT   "NCI series of cell lines: an historical perspective.";
RL   J. Cell. Biochem. 63 Suppl. 24:1-11(1996).
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
RX   PubMed=8806095; DOI=10.1002/jcb.240630508;
RA   Park J.-G., Gazdar A.F.;
RT   "Biology of colorectal and gastric cancer cell lines.";
RL   J. Cell. Biochem. 63 Suppl. 24:131-141(1996).
RX   PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002;
RA   Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T.,
RA   Noh S.H., Rha S.Y.;
RT   "In vitro pharmacogenomic database and chemosensitivity predictive
RT   genes in gastric cancer.";
RL   Genomics 93:52-61(2009).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=26919099; DOI=10.18632/oncotarget.7575;
RA   Arienti C., Zanoni M., Pignatta S., Del Rio A., Carloni S.,
RA   Tebaldi M., Tedaldi G., Tesei A.;
RT   "Preclinical evidence of multiple mechanisms underlying trastuzumab
RT   resistance in gastric cancer.";
RL   Oncotarget 7:18424-18439(2016).
RX   PubMed=27102572; DOI=10.1002/path.4729;
RA   Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H.,
RA   Zuercher W.J., Turlais F., Ye H.-T., Leite A.P., Smith J.A., Leithner A.,
RA   Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R.,
RA   Strauss S.J., Pillay N., Flanagan A.M.;
RT   "EGFR inhibitors identified as a potential treatment for chordoma in a
RT   focused compound screen.";
RL   J. Pathol. 239:320-334(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).